Long-Term Safety and Effectiveness of Sonelokimab for Hidradenitis Suppurativa
Treatments studied
Part of Infections, Skin clinical trials.
This study offers long-term treatment with an investigational biologic, sonelokimab, for people with moderate to severe hidradenitis suppurativa who finished an earlier sonelokimab study. The goal is to see if sonelokimab remains safe and effective over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You finished a prior sonelokimab study for moderate to severe hidradenitis suppurativa and your doctor said you can continue treatment.
- If you can become pregnant, you must not be pregnant or breastfeeding.
- If you are a male and sexually active with a female partner who could become pregnant, you must use a condom and not donate sperm during the study and for 8 weeks after the last dose.
- You must not have been told to stop the prior study because of a side effect or other problem.
- You must not be using or planning to use any forbidden treatments (like certain other HS drugs) during this study.
- You cannot be enrolled in any other experimental drug or device trial at the same time.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an injected drug called siplizumab for people with moderate to severe hidradenitis suppurativa (HS) that hasn't improved with other treatments. The goal is to see if it safely reduces painful bumps and improves your skin condition.
This study tracks how secukinumab (a new medication) works for hidradenitis suppurativa—a painful skin condition with recurring boils and abscesses—in real-world patient care in Italy. Researchers want to understand treatment patterns and outcomes to help improve care for this condition.
This trial tests a new medication, SAR445399, for people with moderate to severe hidradenitis suppurativa (HS) who haven't improved with oral antibiotics. It aims to see if the drug safely reduces skin bumps and abscesses.
This trial tests a new medicine called HB0043 for people with moderate to severe hidradenitis suppurativa (a skin condition causing painful lumps). It aims to see if the drug is safe and helps reduce symptoms.
This study tests a new medicine called LAD191 for people with moderate to severe hidradenitis suppurativa (HS) who haven't been helped enough by antibiotics. Researchers want to see if LAD191 safely reduces painful bumps and tunnels.
This study tests a new drug called LAD328 for hidradenitis suppurativa (HS), a chronic skin condition with painful lumps and abscesses. The trial is looking for adults with moderate-to-severe HS who haven't responded well to antibiotics to see if this new treatment can help reduce symptoms.
Hear when a new Hidradenitis Suppurativa trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.